Glybera is a gene therapy drug used to treat adults suffering from lipoprotein lipase deficiency (LPLD), an extremely rare metabolic disorder. Information on the composition, application and effect of the gene therapy medicinal product is provided in the summary of the European Public Assessment Report (EPAR) for the authorization of the medicinal product by the European Medicines Agency (EMA).

European Medicines Agency (2015): Glybera. Summary of the EPAR for the public. Online Version

Wird geladen